Shanghai Securities released a research report on April 28 stating that Huadong Pharmaceutical (000963.SZ) was given a purchase rating. The main reasons for the rating include: 1) the pharmaceutical business is growing steadily, and the medical and aesthetic trend is maintaining a good trend; 2) the company's overall operation in East China continues to grow steadily; 3) profitability has improved year-on-year; 4) actively promoting the registration and implementation of key medical and aesthetic products and expecting more products to be approved for domestic listing; 5) ATGC and Chongqing Yuyan Company have made significant progress in developing innovative botulinum toxin products. (Mainichi Keizai Shimbun)
上海证券4月28日发布研报称，给予华东医药（000963.SZ）买入评级。评级理由主要包括：1）医药业务稳定增长，医美保持良好态势；2）公司中美华东整体经营继续保持稳定增长趋势；3）盈利能力同比改善；4）积极推进重点医美产品的注册及落地工作，期待更多产品国内获批上市；5）ATGC及重庆誉颜公司合作引进的两款在研创新型肉毒素产品均取得重要进展。（每日经济新闻）
Shanghai Securities released a research report on April 28 stating that Huadong Pharmaceutical (000963.SZ) was given a purchase rating. The main reasons for the rating include: 1) the pharmaceutical business is growing steadily, and the medical and aesthe
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.